AI Agents Funding 2026: The Startups Raising to Automate Real Work

AI agents — software that takes actions rather than just answering questions — are one of the best-funded categories in AI in 2026. In just the last few months, agent startups across healthcare, finance, sales, and industrial manufacturing have raised hundreds of millions of dollars, with valuations reaching into the billions. Here's a roundup of the biggest AI agent funding rounds Wortins has tracked, and what they say about where the money is going.

The rounds at a glance

Six companies, six different verticals, one shared thesis: agents that do the work are worth more than agents that just describe it.

Assort Health — $120M Series C at a $1.2B valuation

Assort Health builds AI agents that handle patient scheduling for healthcare providers — the phone-tree, hold-music, human-scheduler workflow that most patients still have to fight through. Its $120 million Series C values the company at $1.2 billion, making it the largest and most richly valued round in this roundup. The bet is straightforward: scheduling is a high-volume, rules-heavy, repetitive task that eats enormous front-office labor at hospitals and clinics, and it's exactly the kind of workflow an agent can own end-to-end rather than just assist with.

Trase — $107M seed for regulated-industry agents

Trase raised a $107 million seed round — an unusually large seed check — to build AI agents for regulated industries, specifically healthcare and defense. Both sectors carry compliance, auditability, and safety requirements that make most off-the-shelf agent tooling a nonstarter. Trase's pitch is that agents built from the ground up for regulated environments can clear the bar that general-purpose agents can't, and investors were willing to fund that thesis at a scale usually reserved for later rounds.

LinqAlpha — $22M Series A for institutional investors

LinqAlpha is building AI agents for institutional investors, automating the research and analysis grind that hedge funds and asset managers pay analysts to do. Its $22 million Series A is smaller than the others here, but finance is a natural fit for agentic AI: the work is data-heavy, repetitive across companies and filings, and the cost of a good analyst is high enough that even partial automation pencils out fast.

Aligned — $60M Series B for B2B sales

Aligned describes itself as a "system of action" for B2B sales — agents that don't just log activity in a CRM but actually execute parts of the sales motion. The $60 million Series B puts it among the better-funded companies applying agents to revenue teams, a category that's grown crowded but where actual task-completion (versus note-taking and summarization) is still the differentiator investors are paying up for.

Bespoke Labs — $40M Series A for agent infrastructure

Bespoke Labs sits a layer beneath the application-facing agents on this list. It builds data curation and reinforcement-learning environments used to train autonomous agents — the infrastructure that makes other companies' agents better at completing tasks reliably. Its $40 million Series A is a bet on the picks-and-shovels side of the agent boom: as more companies build agents, more of them will need training environments and curated data to make those agents trustworthy.

Katalyze AI — ~$10.5M for agentic AI in pharma manufacturing

Katalyze AI is applying agentic AI to pharma manufacturing, one of the most operationally constrained environments in the group. Its roughly $10.5 million round is the smallest here, but pharma manufacturing is a market where even modest efficiency gains carry outsized value, given how tightly regulated and expensive downtime is in that industry.

Why AI agents are attracting so much capital

Across these six deals, a few patterns explain why "AI agents" has become one of the hottest funded categories of 2026:

1. Agents replace cost centers, not just workflows. A chatbot that answers questions is a nice-to-have. An agent that schedules patients, executes trades research, or runs a manufacturing step is replacing headcount or overtime — a much easier ROI case for a buyer to sign off on, and a much easier story for a founder to sell to investors.
2. Vertical specificity is winning over general-purpose agents. None of these six companies are building a horizontal "agent platform." They're all narrow: healthcare scheduling, regulated compliance, institutional research, B2B sales execution, agent training infrastructure, pharma operations. Investors are rewarding depth in a single workflow over breadth across many.
3. Regulated industries are no longer no-go zones. Trase's $107 million seed for healthcare-and-defense agents, and Katalyze AI's pharma-manufacturing round, show that "too regulated for AI" is becoming outdated as a filter. If anything, regulation is turning into a moat — once a startup clears compliance in healthcare or defense, it's much harder for a general-purpose competitor to catch up.
4. The stack is being funded top to bottom. Bespoke Labs' round shows investors aren't just backing the agents customers see — they're backing the infrastructure layer (RL environments, curated data) that makes those agents good enough to trust with real tasks in the first place.

Valuations tell the same story from a different angle. Assort Health's $1.2 billion mark, on a $120 million round, implies investors believe healthcare scheduling agents can scale into a business worth multiples of what's been raised so far — not just a feature bolted onto existing health IT vendors, but a standalone category winner.

For a broader view of how agent funding compares to the rest of 2026's AI capital, see Wortins' roundup of the biggest AI funding rounds of 2026. And for daily tracking of new raises as they're announced, check the AI Funding Tracker.

Wortins tracks AI agent funding, valuations, and new rounds as they're announced. Bookmark the AI Funding Tracker to follow what's next.